Latest revenue
$1.0M
as of 2026-03-31
Latest net income
$-6.7M
as of 2026-03-31
Net margin
-650.8%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Services-Testing Laboratories (5 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think BNBX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.8M
- Enterprise value
- $3.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.30×
- Dividend yield
- 0.0%
- 52-wk high
- $6.17
- 52-wk low
- $0.37
- Beta
- —
- Shares out
- 7.2M
5-year trend
What this company does
ITEM 1.BUSINESS. Overview We are a digital asset treasury (“DAT”) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem as our primary reserve asset. By using proceeds from financings, as well as potential cashflow from our operations, we seek to strategically accumulate BNB and utilize the accumulated BNB as a productive treasury asset to produce yield via Binance native and other decentralized (DeFi) finance opportunities. In addition, via our LineaRx, Inc. subsidiary (“LineaRx”), we are commercializing proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. Our nucleic acid production solutions enable…
AI summary unavailable — showing raw filing excerpt
Generated from BNBX's filing dated 2025-12-22
Key risks
ITEM 1A.RISK FACTORS. Summary of Risk Factors Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks: Risks Related to Our Business ●We may not successfully implement our business strategies, including achieving our growth objectives and the implementation of our BNB digital treasury strategy. ●We may not successfully implement our business strategies for our Therapeutic DNA Production Services, including but not limited to the sale or licensing of our technologies. ●We have identified a material weakness in our internal controls over financial reporting. ●Sales of a…
AI summary unavailable — showing raw filing excerpt
Generated from BNBX's filing dated 2025-12-22
Profitability
Gross margin
39.3%
32.5%Operating margin
-750.9%
83.7%Net margin
-709.5%
248.2%Return on equity
-657.8%
760.1%Return on assets
-341.7%
524.9%Leverage
Debt / equity
0.93×
132.0%Debt / assets
48.1%
68.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.0M | +34.3% | $-6.7M | -101.7% | -650.8% |
Q4 2025 2025-12-31 | $565.4K | -35.0% | $-18.6M | -604.5% | -3288.6% |
Q3 2025 2025-09-30 | $199.4K | -82.5% | $-5.3M | -59.9% | -2643.4% |
Q2 2025 2025-06-30 | $304.4K | -35.6% | $-3.9M | -309.9% | -1296.1% |
Q1 2025 2025-03-31 | $762.8K | -17.9% | $-3.3M | +26.1% | -433.2% |
Q4 2024 2024-12-31 | $870.3K | -2.3% | $-2.6M | -138.8% | -303.3% |
Q3 2024 2024-09-30 | $1.1M | — | $-3.3M | — | -289.7% |
Q2 2024 2024-06-30 | $472.8K | -83.8% | $1.9M | +160.6% | 397.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Testing Laboratories · SIC 8734
Your notes
Keep private notes on BNBX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BNBX
Institutional value
$16.5K
Total shares held
25.8K
Distinct holders
11
-10 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD FIDUCIARY TRUST CO | 16.7K | $10.7K | — | New |
| 2 | UBS Group AG | 8.6K | $5.5K | +4.5K (+108.5%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 386 | $247 | — | New |
| 4 | SBI Securities Co., Ltd. | 145 | $93 | -1 (-0.7%) | Trimmed |
| 5 | BlackRock, Inc. | 4 | $3 | +0 (+0.0%) | No change |
| 6 | DANSKE BANK A/S | 1 | $1 | +0 (+0.0%) | No change |
| 7 | Caitong International Asset Management Co., Ltd | 1 | $1 | — | New |
| 8 | WELLS FARGO & COMPANY/MN | 1 | $1 | +0 (+0.0%) | No change |
| 9 | Westside Investment Management, Inc. | 1 | $1 | +0 (+0.0%) | No change |
| 10 | Kohmann Bosshard Financial Services, LLC | 1 | $1 | +0 (+0.0%) | No change |
| 11 | Community Financial Services Group, LLC | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BNBX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.